查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1933350

全球成人疫苗市場：市場規模、佔有率、成長率、產業分析、依類型、應用和地區劃分的考量因素以及未來預測（2026-2034）

Adults Vaccines Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 220 Pages | 商品交期: 請詢問到貨日

價格

成人疫苗市場成長因素

受成人傳染病發病率上升、人口老化以及成人疫苗接種意識增強等因素的推動，全球成人疫苗市場正經歷強勁增長。根據 Fortune Business Insights 預測，到 2025 年，全球成人疫苗市場規模預計將達到 420.6 億美元。預計該市場將從 2026 年的 452.2 億美元成長到 2034 年的 1,064.3 億美元，預測期內複合年增長率 (CAGR) 為 11.29%。北美地區憑藉較高的疫苗接種率和先進的醫療保健基礎設施，在 2025 年將以 48.16% 的市佔率領先。

成人疫苗接種在保護個人和社區免受嚴重甚至危及生命的疾病侵害方面發揮著至關重要的作用。隨著年齡增長，免疫功能逐漸下降，成人更容易感染流感、肺炎、肝炎和帶狀皰疹等傳染病。醫療關注度的提高、強有力的政府政策以及疫苗平台技術的進步，持續推動市場擴張。

市場動態

市場驅動因素

成人傳染病發生率的上升是市場成長的主要驅動因素。生活方式的改變、抗菌素抗藥性、人口老化以及慢性病盛行率的增加等因素都導致了感染率的上升，從而顯著增加了對預防性疫苗的需求。例如，根據美國疾病管制與預防中心 (CDC) 於 2024 年 8 月發布的數據，美國 18 至 64 歲成年人中每年有超過 8.8% 的人感染流感，這凸顯了成人疫苗接種計畫的必要性。

市場限制因子

疫苗猶豫和錯誤訊息仍是限制市場成長的主要因素。透過社群媒體平台傳播的誤導性訊息會對大眾對疫苗的信任產生負面影響。在某些地區，文化和宗教信仰也會進一步影響疫苗接種決定。根據2024年11月發表的一篇醫學期刊文章，約有38.4%的成年人對接種新冠疫苗持猶豫態度，可能會限制預測期內的市場擴張。

市場機會

疫苗研發領域的技術進步帶來了巨大的成長機會。 mRNA平台和新型製劑的應用提高了疫苗的有效性和安全性。這些進步有望提高成人疫苗接種率並減輕疾病負擔。 2025年5月，Moderna宣布其mRNA平台可應用於傳染病、免疫腫瘤和自體免疫疾病的疫苗研發，凸顯了其未來的成長潛力。

市場挑戰

成人疫苗接種意識不足仍然是一個重大挑戰，尤其是在新興經濟體。對疫苗益處和安全性的認知不足往往會導致接種延遲或不接種。葛蘭素史克公司 (GSK plc) 於 2025 年 2 月進行的一項調查發現，超過 56.6% 的 50 歲及以上印度受訪者不了解帶狀皰疹（皰疹病毒感染），這可能會阻礙疫苗的普及。

成人疫苗市場趨勢

聯合疫苗的研發已成為顯著的市場趨勢。聯合疫苗減少了所需的注射次數，提高了接種的便利性和依從性。預計流感、新冠病毒和呼吸道合胞病毒 (RSV) 的聯合疫苗將越來越受歡迎。此外，世界各國政府正在根據世界衛生組織 (WHO) 的建議，採取終身接種策略，這將支持市場的長期成長。

依細分市場分析

依類型劃分，重組/結合/次單位疫苗細分市場在2024年佔市場主導地位，這主要得益於其高效性和長期免疫保護。滅活疫苗細分市場也佔了相當大的佔有率，這得益於其廣泛的疾病覆蓋範圍和成本效益。

依給藥途徑劃分，腸外給藥細分市場在2024年佔市場主導地位，這主要得益於其高生物利用度和快速起效。口服細分市場預計將穩定成長，這主要歸功於其給藥便利性和安全性提高。

依疾病劃分，病毒性疾病細分市場在2024年佔市場主導地位，這主要得益於流感、肝炎和帶狀皰疹的高發生率。由於人們對抗菌素抗藥性的日益關注，細菌性疾病細分市場也做出了顯著貢獻。

依分銷管道劃分，政府供應商在2024年佔市場主導地位，這得益於大規模疫苗接種計劃和國際採購舉措。

區域展望

北美地區擁有強大的疫苗接種基礎設施和有利的監管框架，預計將引領市場，2025年市場規模將達到194.5億美元，2026年將達到209.2億美元。

歐洲由於政府支出高且積極的疫苗研發舉措，佔了較大的市場佔有率。

亞太地區是成長最快的地區，這主要得益於高疾病盛行率、不斷擴大的疫苗接種計畫和日益活躍的研發活動。

拉丁美洲以及中東和非洲地區預計將保持穩定成長，這得益於人們對先進疫苗的認識和需求不斷提高。

目錄

第一章：引言

第二章：摘要整理

第三章：市場動態

  • 市場驅動因素
  • 市場限制因素
  • 市場機遇
  • 市場趨勢

第四章：關鍵考慮因素

  • 主要國家/地區主要疾病的發生率/盛行率（2025 年）
  • 成人疫苗的技術進步
  • 主要公司的新產品發布
  • 主要公司的研發管線分析
  • 主要產業趨勢：併購、業務合作等等。

第五章 全球成人疫苗市場分析、洞察與預測（2021-2034）

  • 市場分析、洞察與預測：依類型劃分
    • 重組/結合/次單位疫苗
    • 滅活​​疫苗
    • mRNA疫苗
    • 病毒載體疫苗
    • 減毒活疫苗
    • 類毒素疫苗
    • 其他
  • 市場分析、洞察與預測：依給藥途徑劃分
    • 腸外給藥
    • 口服
  • 市場分析、洞察與預測：依疾病劃分
    • 病毒性疾病
      • 肝炎
      • 流感
      • 人類用疫苗皮洛馬病毒
      • 帶狀皰疹
      • 其他
    • 細菌性疾病
      • 腦膜炎雙球菌感染
      • 肺炎鏈球菌感染
      • 白喉、破傷風和百日咳
      • 其他
  • 市場分析、洞察與預測：依銷售管道劃分
    • 醫院和零售藥局
    • 政府供應商
    • 其他
  • 市場分析、洞察與預測：依地區劃分
    • 北美
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第六章 北美成人疫苗市場分析：洞察與預測 （2021-2034）

  • 依國家劃分
    • 美國
    • 加拿大

第七章：歐洲成人疫苗市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 英國
    • 德國
    • 法國
    • 西班牙
    • 義大利
    • 斯堪的納維亞
    • 歐洲其他地區

第八章：亞太地區成人疫苗市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 日本
    • 中國
    • 印度
    • 澳大利亞
    • 東南亞亞洲
    • 亞太其他地區

第九章：拉丁美洲成人疫苗市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地區

第十章：中東與非洲成人疫苗市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 海灣合作委員會（GCC）成員國
    • 南非
    • 中東和非洲其他地區

第十一章 競爭分析

  • 全球市佔率分析（2025）
  • 公司型材
    • Bavarian Nordic
    • GSK plc
    • EMERGENT
    • Merck &Co., Inc.
    • Inovio Pharmaceuticals, Inc.
    • Pfizer Inc.
    • Sanofi
    • CSL
    • AstraZeneca
Product Code: FBI113663

Growth Factors of adults vaccines Market

The global adults vaccines market is experiencing strong growth, supported by the rising burden of infectious diseases among adults, increasing geriatric population, and growing awareness regarding adult immunization. According to Fortune Business Insights, the global adults vaccines market was valued at USD 42.06 billion in 2025. The market is projected to grow from USD 45.22 billion in 2026 to USD 106.43 billion by 2034, registering a CAGR of 11.29% during the forecast period. In 2025, North America dominated the market with a share of 48.16%, driven by high vaccine uptake and advanced healthcare infrastructure.

Adult vaccination plays a critical role in protecting individuals and communities from serious and life-threatening diseases. As immune function declines with age, adults become more vulnerable to infections such as influenza, pneumonia, hepatitis, and shingles. The growing focus on preventive healthcare, along with strong government initiatives and technological advancements in vaccine platforms, continues to support market expansion.

Market Dynamics

Market Drivers

The increasing incidence of infectious diseases among adults is a major driver of market growth. Factors such as lifestyle changes, antimicrobial resistance, aging populations, and rising prevalence of chronic conditions have contributed to higher infection rates. This has significantly increased the demand for preventive vaccines. For instance, data published by the Centers for Disease Control and Prevention in August 2024 highlighted that influenza affects more than 8.8% of adults aged 18-64 annually in the U.S., underlining the growing need for adult vaccination programs.

Market Restraints

Vaccine hesitancy and misinformation remain key restraints for market growth. Misleading information shared through social media platforms has negatively impacted public trust in vaccines. Cultural and religious beliefs further influence vaccination decisions in certain regions. According to a medical journal published in November 2024, nearly 38.4% of adults expressed hesitancy toward COVID-19 vaccination, which may limit market expansion during the forecast period.

Market Opportunities

Technological advancements in vaccine development present significant growth opportunities. The adoption of mRNA platforms and novel formulations has improved vaccine efficacy and safety profiles. These advancements are expected to increase adult vaccination rates and reduce disease burden. In May 2025, Moderna announced that its mRNA platform could be applied to develop vaccines for infectious diseases, immuno-oncology, and autoimmune conditions, highlighting future growth potential.

Market Challenges

Lack of awareness regarding adult vaccination remains a critical challenge, particularly in emerging economies. Insufficient knowledge about vaccine benefits and safety often leads to delayed or missed immunizations. In February 2025, a survey conducted by GSK plc. revealed that over 56.6% of Indian participants aged 50 years and above were unaware of shingles disease, which may hinder vaccine adoption.

Adults Vaccines Market Trends

The development of combination vaccines has emerged as a prominent market trend. Combination vaccines reduce the number of injections required, improving convenience and compliance. Vaccines combining influenza, COVID-19, and RSV are expected to gain traction in the future. Additionally, governments worldwide are adopting life-course immunization strategies aligned with World Health Organization recommendations, supporting long-term market growth.

Segmentation Analysis

By type, the recombinant/conjugate/subunit segment dominated the market in 2024, driven by high efficacy and long-term immune protection. The inactivated vaccines segment also held a significant share due to its broad disease coverage and cost-effectiveness.

By route of administration, the parenteral segment led the market in 2024, supported by high bioavailability and rapid onset of action. The oral segment is expected to grow steadily due to ease of administration and improved safety.

By disease indication, the viral diseases segment dominated the market in 2024, driven by the high prevalence of influenza, hepatitis, and herpes zoster. The bacterial diseases segment also contributed notably due to rising concerns related to antimicrobial resistance.

By distribution channel, government suppliers dominated the market in 2024, supported by large-scale vaccination programs and global procurement initiatives.

Regional Outlook

North America led the market with a valuation of USD 19.45 billion in 2025 and USD 20.92 billion in 2026, supported by strong immunization infrastructure and favorable regulatory frameworks.

Europe held a significant share due to high government spending and active vaccine R&D initiatives.

Asia Pacific is the fastest-growing region, driven by high disease prevalence, expanding immunization programs, and increasing R&D activities.

Latin America and the Middle East & Africa are expected to grow steadily due to rising awareness and demand for advanced vaccines.

Competitive Landscape

The global adults vaccines market is concentrated, with GSK plc., Sanofi, and Serum Institute of India Pvt. Ltd. holding significant market shares. These companies benefit from strong vaccine portfolios, global distribution networks, and continuous product innovation. Other key players include Merck & Co., Inc., Pfizer Inc., AstraZeneca, Bavarian Nordic, and EMERGENT, which continue to invest heavily in research and development.

Conclusion

The global adults vaccines market is poised for robust growth throughout the forecast period, driven by the rising incidence of infectious diseases, expanding geriatric population, and increasing emphasis on preventive healthcare. With the market valued at USD 42.06 billion in 2025, projected to grow to USD 45.22 billion in 2026 and reach USD 106.43 billion by 2034, advancements in vaccine technology, growing government support, and strong industry pipelines are expected to shape the future of adult immunization. Despite challenges related to vaccine hesitancy and awareness gaps, sustained innovation and global immunization initiatives are anticipated to support long-term market expansion.

Segmentation By Type

  • Recombinant/Conjugate/Subunit
  • Inactivated
  • mRNA
  • Viral Vector
  • Live Attenuated
  • Toxoid
  • Others

By Route of Administration

  • Parenteral
  • Oral

By Disease Indication

  • Viral Diseases
    • Hepatitis
    • Influenza
    • Human Papillomavirus
    • Herpes Zoster
    • Others
  • Bacterial Diseases
    • Meningococcal Disease
    • Pneumococcal Disease
    • Diphtheria/Tetanus/Pertussis
    • Others

By Distribution Channel

  • Hospital & Retail Pharmacies
  • Government Suppliers
  • Others

By Region

  • North America (By Type, Route of Administration, Disease Indication, Distribution Channel, and Country)
    • U.S.
    • Canada
  • Europe (By Type, Route of Administration, Disease Indication, Distribution Channel, and Country/Sub-region)
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Type, Route of Administration, Disease Indication, Distribution Channel, and Country/Sub-region)
    • China
    • Japan
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Type, Route of Administration, Disease Indication, Distribution Channel, and Country/Sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Type, Route of Administration, Disease Indication, Distribution Channel, and Country/Sub-region)
    • GCC
    • South Africa
  • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Incidence/Prevalence of Key Diseases, By Key Countries/Regions, 2025
  • 4.2. Technological Advancements in the Adults Vaccines
  • 4.3. New Product Launches, By Key Players
  • 4.4. Pipeline Analysis, By Key Players
  • 4.5. Key Industry Developments Such as Mergers, Acquisitions, and Partnerships

5. Global Adults Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Type
    • 5.1.1. Recombinant/Conjugate/Subunit
    • 5.1.2. Inactivated
    • 5.1.3. mRNA
    • 5.1.4. Viral Vector
    • 5.1.5. Live Attenuated
    • 5.1.6. Toxoid
    • 5.1.7. Others
  • 5.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 5.2.1. Parenteral
    • 5.2.2. Oral
  • 5.3. Market Analysis, Insights and Forecast - By Disease Indication
    • 5.3.1. Viral Diseases
      • 5.3.1.1. Hepatitis
      • 5.3.1.2. Influenza
      • 5.3.1.3. Human Papillomavirus
      • 5.3.1.4. Herpes Zoster
      • 5.3.1.5. Others
    • 5.3.2. Bacterial Diseases
      • 5.3.2.1. Meningococcal Disease
      • 5.3.2.2. Pneumococcal Disease
      • 5.3.2.3. Diphtheria/Tetanus/Pertussis
      • 5.3.2.4. Others
  • 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.4.1. Hospital & Retail Pharmacies
    • 5.4.2. Government Suppliers
    • 5.4.3. Others
  • 5.5. Market Analysis, Insights and Forecast - By Region
    • 5.5.1. North America
    • 5.5.2. Europe
    • 5.5.3. Asia Pacific
    • 5.5.4. Latin America
    • 5.5.5. Middle East & Africa

6. North America Adults Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Type
    • 6.1.1. Recombinant/Conjugate/Subunit
    • 6.1.2. Inactivated
    • 6.1.3. mRNA
    • 6.1.4. Viral Vector
    • 6.1.5. Live Attenuated
    • 6.1.6. Toxoid
    • 6.1.7. Others
  • 6.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 6.2.1. Parenteral
    • 6.2.2. Oral
  • 6.3. Market Analysis, Insights and Forecast - By Disease Indication
    • 6.3.1. Viral Diseases
      • 6.3.1.1. Hepatitis
      • 6.3.1.2. Influenza
      • 6.3.1.3. Human Papillomavirus
      • 6.3.1.4. Herpes Zoster
      • 6.3.1.5. Others
    • 6.3.2. Bacterial Diseases
      • 6.3.2.1. Meningococcal Disease
      • 6.3.2.2. Pneumococcal Disease
      • 6.3.2.3. Diphtheria/Tetanus/Pertussis
      • 6.3.2.4. Others
  • 6.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.4.1. Hospital & Retail Pharmacies
    • 6.4.2. Government Suppliers
    • 6.4.3. Others
  • 6.5. Market Analysis, Insights and Forecast - By Country
    • 6.5.1. U.S.
    • 6.5.2. Canada

7. Europe Adults Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Type
    • 7.1.1. Recombinant/Conjugate/Subunit
    • 7.1.2. Inactivated
    • 7.1.3. mRNA
    • 7.1.4. Viral Vector
    • 7.1.5. Live Attenuated
    • 7.1.6. Toxoid
    • 7.1.7. Others
  • 7.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 7.2.1. Parenteral
    • 7.2.2. Oral
  • 7.3. Market Analysis, Insights and Forecast - By Disease Indication
    • 7.3.1. Viral Diseases
      • 7.3.1.1. Hepatitis
      • 7.3.1.2. Influenza
      • 7.3.1.3. Human Papillomavirus
      • 7.3.1.4. Herpes Zoster
      • 7.3.1.5. Others
    • 7.3.2. Bacterial Diseases
      • 7.3.2.1. Meningococcal Disease
      • 7.3.2.2. Pneumococcal Disease
      • 7.3.2.3. Diphtheria/Tetanus/Pertussis
      • 7.3.2.4. Others
  • 7.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.4.1. Hospital & Retail Pharmacies
    • 7.4.2. Government Suppliers
    • 7.4.3. Others
  • 7.5. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 7.5.1. U.K.
    • 7.5.2. Germany
    • 7.5.3. France
    • 7.5.4. Spain
    • 7.5.5. Italy
    • 7.5.6. Scandinavia
    • 7.5.7. Rest of Europe

8. Asia Pacific Adults Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Type
    • 8.1.1. Recombinant/Conjugate/Subunit
    • 8.1.2. Inactivated
    • 8.1.3. mRNA
    • 8.1.4. Viral Vector
    • 8.1.5. Live Attenuated
    • 8.1.6. Toxoid
    • 8.1.7. Others
  • 8.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 8.2.1. Parenteral
    • 8.2.2. Oral
  • 8.3. Market Analysis, Insights and Forecast - By Disease Indication
    • 8.3.1. Viral Diseases
      • 8.3.1.1. Hepatitis
      • 8.3.1.2. Influenza
      • 8.3.1.3. Human Papillomavirus
      • 8.3.1.4. Herpes Zoster
      • 8.3.1.5. Others
    • 8.3.2. Bacterial Diseases
      • 8.3.2.1. Meningococcal Disease
      • 8.3.2.2. Pneumococcal Disease
      • 8.3.2.3. Diphtheria/Tetanus/Pertussis
      • 8.3.2.4. Others
  • 8.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.4.1. Hospital & Retail Pharmacies
    • 8.4.2. Government Suppliers
    • 8.4.3. Others
  • 8.5. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 8.5.1. Japan
    • 8.5.2. China
    • 8.5.3. India
    • 8.5.4. Australia
    • 8.5.5. Southeast Asia
    • 8.5.6. Rest of Asia Pacific

9. Latin America Adults Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Type
    • 9.1.1. Recombinant/Conjugate/Subunit
    • 9.1.2. Inactivated
    • 9.1.3. mRNA
    • 9.1.4. Viral Vector
    • 9.1.5. Live Attenuated
    • 9.1.6. Toxoid
    • 9.1.7. Others
  • 9.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 9.2.1. Parenteral
    • 9.2.2. Oral
  • 9.3. Market Analysis, Insights and Forecast - By Disease Indication
    • 9.3.1. Viral Diseases
      • 9.3.1.1. Hepatitis
      • 9.3.1.2. Influenza
      • 9.3.1.3. Human Papillomavirus
      • 9.3.1.4. Herpes Zoster
      • 9.3.1.5. Others
    • 9.3.2. Bacterial Diseases
      • 9.3.2.1. Meningococcal Disease
      • 9.3.2.2. Pneumococcal Disease
      • 9.3.2.3. Diphtheria/Tetanus/Pertussis
      • 9.3.2.4. Others
  • 9.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.4.1. Hospital & Retail Pharmacies
    • 9.4.2. Government Suppliers
    • 9.4.3. Others
  • 9.5. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 9.5.1. Brazil
    • 9.5.2. Mexico
    • 9.5.3. Rest of Latin America

10. Middle East & Africa Adults Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Type
    • 10.1.1. Recombinant/Conjugate/Subunit
    • 10.1.2. Inactivated
    • 10.1.3. mRNA
    • 10.1.4. Viral Vector
    • 10.1.5. Live Attenuated
    • 10.1.6. Toxoid
    • 10.1.7. Others
  • 10.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 10.2.1. Parenteral
    • 10.2.2. Oral
  • 10.3. Market Analysis, Insights and Forecast - By Disease Indication
    • 10.3.1. Viral Diseases
      • 10.3.1.1. Hepatitis
      • 10.3.1.2. Influenza
      • 10.3.1.3. Human Papillomavirus
      • 10.3.1.4. Herpes Zoster
      • 10.3.1.5. Others
    • 10.3.2. Bacterial Diseases
      • 10.3.2.1. Meningococcal Disease
      • 10.3.2.2. Pneumococcal Disease
      • 10.3.2.3. Diphtheria/Tetanus/Pertussis
      • 10.3.2.4. Others
  • 10.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.4.1. Hospital & Retail Pharmacies
    • 10.4.2. Government Suppliers
    • 10.4.3. Others
  • 10.5. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 10.5.1. GCC
    • 10.5.2. South Africa
    • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles
    • 11.2.1. Bavarian Nordic
      • 11.2.1.1. Overview
      • 11.2.1.2. Products
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. Financials (Based on Availability)
    • 11.2.2. GSK plc
      • 11.2.2.1. Overview
      • 11.2.2.2. Products
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. Financials (Based on Availability)
    • 11.2.3. EMERGENT
      • 11.2.3.1. Overview
      • 11.2.3.2. Products
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. Financials (Based on Availability)
    • 11.2.4. Merck & Co., Inc.
      • 11.2.4.1. Overview
      • 11.2.4.2. Products
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. Financials (Based on Availability)
    • 11.2.5. Inovio Pharmaceuticals, Inc.
      • 11.2.5.1. Overview
      • 11.2.5.2. Products
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. Financials (Based on Availability)
    • 11.2.6. Pfizer Inc.
      • 11.2.6.1. Overview
      • 11.2.6.2. Products
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. Financials (Based on Availability)
    • 11.2.7. Sanofi
      • 11.2.7.1. Overview
      • 11.2.7.2. Products
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. Financials (Based on Availability)
    • 11.2.8. CSL
      • 11.2.8.1. Overview
      • 11.2.8.2. Products
      • 11.2.8.3. SWOT Analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. Financials (Based on Availability)
    • 11.2.9. AstraZeneca
      • 11.2.9.1. Overview
      • 11.2.9.2. Products
      • 11.2.9.3. SWOT Analysis
      • 11.2.9.4. Recent Developments
      • 11.2.9.5. Strategies
      • 11.2.9.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Adults Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 2: Global Adults Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 3: Global Adults Vaccines Market Revenue (USD billion) Forecast, by Disease Indication, 2021-2034
  • Table 4: Global Adults Vaccines Market Revenue (USD billion) Forecast, by Viral Diseases, 2021-2034
  • Table 5: Global Adults Vaccines Market Revenue (USD billion) Forecast, by Bacterial Diseases, 2021-2034
  • Table 6: Global Adults Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 7: Global Adults Vaccines Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 8: North America Adults Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 9: North America Adults Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 10: North America Adults Vaccines Market Revenue (USD billion) Forecast, by Disease Indication, 2021-2034
  • Table 11: North America Adults Vaccines Market Revenue (USD billion) Forecast, by Viral Diseases, 2021-2034
  • Table 12: North America Adults Vaccines Market Revenue (USD billion) Forecast, by Bacterial Diseases, 2021-2034
  • Table 13: North America Adults Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 14: North America Adults Vaccines Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 15: Europe Adults Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 16: Europe Adults Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 17: Europe Adults Vaccines Market Revenue (USD billion) Forecast, by Disease Indication, 2021-2034
  • Table 18: Europe Adults Vaccines Market Revenue (USD billion) Forecast, by Viral Diseases, 2021-2034
  • Table 19: Europe Adults Vaccines Market Revenue (USD billion) Forecast, by Bacterial Diseases, 2021-2034
  • Table 20: Europe Adults Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 21: Europe Adults Vaccines Market Revenue (USD billion) Forecast, By Country/Sub-region, 2021-2034
  • Table 22: Asia Pacific Adults Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 23: Asia Pacific Adults Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 24: Asia Pacific Adults Vaccines Market Revenue (USD billion) Forecast, by Disease Indication, 2021-2034
  • Table 25: Asia Pacific Adults Vaccines Market Revenue (USD billion) Forecast, by Viral Diseases, 2021-2034
  • Table 26: Asia Pacific Adults Vaccines Market Revenue (USD billion) Forecast, by Bacterial Diseases, 2021-2034
  • Table 27: Asia Pacific Adults Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 28: Asia Pacific Adults Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 29: Latin America Adults Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 30: Latin America Adults Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 31: Latin America Adults Vaccines Market Revenue (USD billion) Forecast, by Disease Indication, 2021-2034
  • Table 32: Latin America Adults Vaccines Market Revenue (USD billion) Forecast, by Viral Diseases, 2021-2034
  • Table 33: Latin America Adults Vaccines Market Revenue (USD billion) Forecast, by Bacterial Diseases, 2021-2034
  • Table 34: Latin America Adults Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 35: Latin America Adults Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 36: Middle East & Africa Adults Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 37: Middle East & Africa Adults Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 38: Middle East & Africa Adults Vaccines Market Revenue (USD billion) Forecast, by Disease Indication, 2021-2034
  • Table 39: Middle East & Africa Adults Vaccines Market Revenue (USD billion) Forecast, by Viral Diseases, 2021-2034
  • Table 40: Middle East & Africa Adults Vaccines Market Revenue (USD billion) Forecast, by Bacterial Diseases, 2021-2034
  • Table 41: Middle East & Africa Adults Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 42: Middle East & Africa Adults Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global Adults Vaccines Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global Adults Vaccines Market Value Share (%), by Type, 2025 & 2034
  • Figure 3: Global Adults Vaccines Market Value Share (%), by Route of Administration, 2025 & 2034
  • Figure 4: Global Adults Vaccines Market Value Share (%), by Disease Indication, 2025 & 2034
  • Figure 5: Global Adults Vaccines Market Value Share (%), by Distribution Channel, 2025 & 2034
  • Figure 6: Global Adults Vaccines Market Value Share (%), by Region, 2025 & 2034
  • Figure 7: North America Adults Vaccines Market Value (USD billion), by Type, 2025 & 2034
  • Figure 8: North America Adults Vaccines Market Value Share (%), by Type, 2025
  • Figure 9: North America Adults Vaccines Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 10: North America Adults Vaccines Market Value Share (%), by Route of Administration, 2025
  • Figure 11: North America Adults Vaccines Market Value (USD billion), by Disease Indication, 2025 & 2034
  • Figure 12: North America Adults Vaccines Market Value Share (%), by Disease Indication, 2025
  • Figure 13: North America Adults Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 14: North America Adults Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 15: North America Adults Vaccines Market Value (USD billion), By Country, 2025 & 2034
  • Figure 16: North America Adults Vaccines Market Value Share (%), By Country, 2025
  • Figure 17: Europe Adults Vaccines Market Value (USD billion), by Type, 2025 & 2034
  • Figure 18: Europe Adults Vaccines Market Value Share (%), by Type, 2025
  • Figure 19: Europe Adults Vaccines Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 20: Europe Adults Vaccines Market Value Share (%), by Route of Administration, 2025
  • Figure 21: Europe Adults Vaccines Market Value (USD billion), by Disease Indication, 2025 & 2034
  • Figure 22: Europe Adults Vaccines Market Value Share (%), by Disease Indication, 2025
  • Figure 23: Europe Adults Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 24: Europe Adults Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 25: Europe Adults Vaccines Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 26: Europe Adults Vaccines Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 27: Asia Pacific Adults Vaccines Market Value (USD billion), by Type, 2025 & 2034
  • Figure 28: Asia Pacific Adults Vaccines Market Value Share (%), by Type, 2025
  • Figure 29: Asia Pacific Adults Vaccines Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 30: Asia Pacific Adults Vaccines Market Value Share (%), by Route of Administration, 2025
  • Figure 31: Asia Pacific Adults Vaccines Market Value (USD billion), by Disease Indication, 2025 & 2034
  • Figure 32: Asia Pacific Adults Vaccines Market Value Share (%), by Disease Indication, 2025
  • Figure 33: Asia Pacific Adults Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 34: Asia Pacific Adults Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 35: Asia Pacific Adults Vaccines Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 36: Asia Pacific Adults Vaccines Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 37: Latin America Adults Vaccines Market Value (USD billion), by Type, 2025 & 2034
  • Figure 38: Latin America Adults Vaccines Market Value Share (%), by Type, 2025
  • Figure 39: Latin America Adults Vaccines Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 40: Latin America Adults Vaccines Market Value Share (%), by Route of Administration, 2025
  • Figure 41: Latin America Adults Vaccines Market Value (USD billion), by Disease Indication, 2025 & 2034
  • Figure 42: Latin America Adults Vaccines Market Value Share (%), by Disease Indication, 2025
  • Figure 43: Latin America Adults Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 44: Latin America Adults Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 45: Latin America Adults Vaccines Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 46: Latin America Adults Vaccines Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 47: Middle East & Africa Adults Vaccines Market Value (USD billion), by Type, 2025 & 2034
  • Figure 48: Middle East & Africa Adults Vaccines Market Value Share (%), by Type, 2025
  • Figure 49: Middle East & Africa Adults Vaccines Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 50: Middle East & Africa Adults Vaccines Market Value Share (%), by Route of Administration, 2025
  • Figure 51: Middle East & Africa Adults Vaccines Market Value (USD billion), by Disease Indication, 2025 & 2034
  • Figure 52: Middle East & Africa Adults Vaccines Market Value Share (%), by Disease Indication, 2025
  • Figure 53: Middle East & Africa Adults Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 54: Middle East & Africa Adults Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 55: Middle East & Africa Adults Vaccines Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 56: Middle East & Africa Adults Vaccines Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 57: Global Adults Vaccines Market Share (%), By Company, 2025